Table 4. Adverse events (AEs).

AEs	Total (n=403)
	All grade	Grade 3–4
Hematological AEs, n (%)
Anemia	234 (58.1)	22 (5.5)
White blood cell count decreased	76 (18.9)	10 (2.5)
Platelet count decreased	61 (15.1)	5 (1.2)
Neutrophil count decreased	56 (13.9)	9 (2.2)
Non-hematological AEs, n (%)
Hypoalbuminemia	136 (33.7)	0 (0.0)
Reactive cutaneous capillary endothelial proliferation	75 (18.6)	0 (0.0)
Elevated transaminase	50 (12.4)	2 (0.5)
Proteinuria	35 (8.7)	0 (0.0)
Fatigue	30 (7.4)	1 (0.2)
Nausea/vomiting	27 (6.7)	1 (0.2)
Fever	26 (6.5)	2 (0.5)
Hyperbilirubinemia	23 (5.7)	1 (0.2)
Immune-related pneumonitis	18 (4.5)	3 (0.7)
Decreased appetite	17 (4.2)	0 (0.0)
Rash	16 (4.0)	1 (0.2)
Pain	14 (3.5)	0 (0.0)
Creatinine increased	12 (3.0)	0 (0.0)
Wheezing and tightness in the chest	11 (2.7)	1 (0.2)
Cough	10 (2.5)	0 (0.0)